Transition period for streamlined drug submissions in Australia to end in October
This article was originally published in SRA
The 12-month transition period that Australia's Therapeutic Goods Administration implemented as part of its new streamlined submission process for prescription medicines will finish at the end of October1.
You may also be interested in...
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.